ClinicalTrials.gg
TerminatedNCT04171843Updated Sep 21, 2023

A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma

A Phase 1 interventional study of PBCAR269A and Fludarabine in Relapsed/Refractory Multiple Myeloma, sponsored by Precision BioSciences, Inc.. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by Precision BioSciences, Inc. · Phase 1, Interventional, and Treatment

Why this study was terminated
Study was terminated due to lack of sufficient therapeutic effect

From the registry’s dates

  • Primary completion was Oct 2022, 4 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,168 studies in Multiple Myeloma with a site in United States — 275 open to participants now, 503 under way, 66 of them phase 3. Multiple Myeloma · United States.

Enrollment
772nd of 1,901
48 · median 36
Started
2020
with 81 others
Phase 1
559 of 2,168
64 open now
Registered
1,585th of 2,168
by date

Among the 2,168 studies in Multiple Myeloma with a site in United States, this one is the 772nd largest by enrollment of the 1,901 interventional ones that give a count, is one of 82 that started in 2020, is one of 559 in phase 1, and was the 1,585th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

275 of the 2,168 studies in Multiple Myeloma with a site in United States are open now. Recruiting first, the newest first:

270 more — sign in →

All 275 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,168 studies in Multiple Myeloma with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR269A, with or without nirogacestat, in adults with r/r MM. Study subjects in Cohort A will receive PBCAR269A and study subjects in Cohort B will receive PBCAR269A and nirogacestat. At each dose level, study subjects in Cohort A and Cohort B will receive the same dose of PBCAR269A. In Cohort B, all study subjects will follow the same dosing regimen of nirogacestat. This study was terminated prior to beginning of Phase II due to lack of sufficient therapeutic effect

Read the detailed description

This is a multicenter, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR269A, with or without nirogacestat, in adults with r/r MM. Before initiating the study treatment PBCAR269A, all study participants will be administered lymphodepletion chemotherapy. The initial lymphodepletion chemotherapy regimen will be composed of fludarabine and cyclophosphamide during the Screening Period. Study subjects in Cohort B will also receive nirogacestat. On Day 0 of the Treatment Period, study participants will receive a single intravenous (IV) infusion of PBCAR269A. All subjects are monitored during the treatment period through Day 28. All subjects who receive a dose of PBCAR269A, with or without nirogacestat, will be followed in a separate long-term follow-up (LTFU) study for 15 years after exiting this study.

03

Conditions studied

  • Relapsed/Refractory Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of MM with disease according to the IMWG criteria.
  2. at Screening including at least 1 of the criteria below. Note: Study participants with immunoglobulin (Ig) A myeloma in whom serum protein electrophoresis is deemed unreliable due to comigration of normal serum proteins with the paraprotein in the beta region may be considered eligible provided total serum IgA level is >400 mg/dL.

    1. Serum myeloma (M)-protein ≥0.5 g/dL or, urine M-protein >200 mg/24 hour.
    2. Serum free light chain >10mg/dL with abnormal kappa:lambda ratio.
    3. Imaging consistent plasmacytoma and the presence of any clonal plasma cells in peripheral blood or bone marrow.
  3. Study participants must be refractory to 2 prior MM treatment regimens including an immunomodulatory imide drug and a protease inhibitor prior to entering the study. Study participants must have recovered or stabilized to Grade ≤2 from any AEs experienced during prior treatment with the exception of neuropathy. Prior therapy requirements are as follows:

    1. Undergone ≥1 complete cycle of treatment for each regimen, unless progressive disease was the best response to the regimen.
    2. Must have received an immunomodulatory agent, a proteasome inhibitor, and an anti- CD38 antibody.
    3. Study participants who are not candidates for ≥1 of the above treatments may still be considered eligible.
  4. Has an (ECOG) Performance Status score of 0 or 1.
  5. Has adequate bone marrow, renal, hepatic, pulmonary, and cardiac function defined as:

    1. Estimated >30 mL/min/1.73 m2. A 24-hour urine collection for may be used at the investigator's discretion.
    2. (ALT) and aspartate aminotransferase (AST) levels both

      ≤3 times of , unless there is suspected disease in the liver, in which case, no limit is set provided serum is within eligibility criterion.

    3. Total bilirubin \<2.0 mg/dL, except in study participants with Gilbert's syndrome.
    4. count >50,000/μL (platelet transfusions acceptable); neutrophils >750/μL.
    5. (LVEF) >45% as assessed by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan performed within 1 month before starting lymphodepleting chemotherapy. ECHO results performed within 6 months before Screening and at least 28 days after the last cancer treatment may be acceptable if the study participant has not received any treatment with cardiotoxicity risks.
    6. No evidence of pericardial effusion or pleural effusion based on investigator's opinion.
    7. Baseline oxygen saturation >92% on room air.
    8. Pulmonary function tests including forced expiratory volume at 1 sec, forced vital capacity, total lung capacity, diffusion capacity of lung for carbon monoxide ≥50% of predicted values. Study participant characteristics
  6. All study participants must be willing to practice and refrain from donating sperm or oocytes from the time of enrollment in this study through 6 months after receiving the study treatment.
  7. Women of (WOCBP) must test negative for pregnancy at Screening because of the potentially harmful effects of the preparative chemotherapy to the fetus. WOCBP are defined as any women who are not or who have not had a hysterectomy. Postmenopausal is defined as women over the age of 55 who have not had a menstrual period for ≥1 year.
  8. Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  1. Study participant has organ involvement by amyloid protein.
  2. Study participant has plasma cell leukemia, Waldenstrom's macroglobulinemia, or POEMS syndrome.
  3. History of class III or IV congestive heart failure or severe non-ischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 6 months of starting study treatment.
  4. History or presence of clinically relevant central nervous system (CNS) pathology.
  5. Active uncontrolled fungal, bacterial, viral, protozoal, or other infection.
  6. Any form of primary immunodeficiency (e.g., severe combined immunodeficiency disease).
  7. History of (HIV) infection.
  8. Active or confirmed by polymerase chain reaction (PCR). Study participant positive for inactive hepatitis B will be allowed to enroll if on prophylactic treatment.
  9. History of hypertension crisis or hypertensive encephalopathy within 3 months prior to Screening.
  10. History of severe immediate reaction to any of the agents used in this study.
  11. Abnormal findings during the Screening Period or any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardize the study participant's safety.
  12. History of genetic syndrome such as Fanconi anemia, Kostmann syndrome, Shwachman-Diamond syndrome, or any other known bone marrow failure syndrome.
  13. Study participants with active hemolytic anemia.
  14. Study participant has received stem cell transplant within 12 weeks of Screening or an allogeneic stem cell transplant within 6 months of starting study treatment. Study participants who have received an allogeneic transplant must be off all medications for 6 weeks without signs of GvHD.
  15. Study participants with second in addition to MM if the second malignancy has required treatment within the last 3 years or is not in complete remission, with the exception of non- basal cell or squamous cell skin carcinoma.
  16. Study participant has received systemic biologic agent within 28 days. Participation in non-interventional registries or epidemiological studies is not excluded.
  17. Study participant has received within 4 weeks before Screening. Non-live virus vaccines are not excluded.
  18. Before initiation of lymphodepletion, study participants must have recovered or stabilized to Grade ≤2 from any AEs experienced during prior treatment with the exception of neuropathy.
  19. Radiotherapy within 4 weeks before Screening should be discussed with the monitor.
  20. Presence of pleural/peritoneal/pericardial catheter.
  21. Current use of any anticoagulant or antiplatelet therapy.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    PBCAR269A at Dose Level 1 (Cohort A)

    The starting dose of PBCAR269A will be 6 x 10\^5 CAR T cells/kg body weight.

    Genetic: PBCAR269A · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    PBCAR269A at Dose Level 2

    2 × 10\^6 CAR T cells/kg body weight.

    Genetic: PBCAR269A · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    PBCAR269A at Dose Level 3

    6 × 10\^6 CAR T cells/kg body weight.

    Genetic: PBCAR269A · Drug: Fludarabine · Drug: Cyclophosphamide

  • Experimental
    PBCAR269A at Dose Level 2 (Cohort B)

    2 × 10\^6 CAR T cells/kg body weight.

    Genetic: PBCAR269A · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Nirogacestat

  • Experimental
    PBCAR269A at Dose Level 1 (Cohort B)

    6 x 10\^5 CAR T cells/kg body weight.

    Genetic: PBCAR269A · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Nirogacestat

  • Experimental
    PBCAR269A at Dose Level 3 (Cohort B)

    6 × 10\^6 CAR T cells/kg body weight.

    Genetic: PBCAR269A · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Nirogacestat

Interventions

  • GeneticPBCAR269A

    Allogeneic anti-BCMA CAR T-cell

  • Fludarabine is used for lymphodepletion.

  • Cyclophosphamide is used for lymphodepletion.

  • Allogeneic anti-BCMA CAR T-cell

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD) of PBCAR269A

    To determine the maximum tolerated dose (MTD), which is defined as the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy.

    Time frame: Day 1 - Day 28

Secondary outcomes

  1. Number of Participants with Dose Limiting Toxicity(ies)

    To assess adverse events as dose limiting toxicities as defined by the protocol and CTCAE v5.0.

    Time frame: 1 year

  2. Objective Response Rate of Patients

    To assess ORR to treatment with PBCAR269A through Day 360 will be noted using the IMWG response criteria. The ORR is defined as the proportion of study participants meeting the definition of response within the study population to the response evaluable population. ORR will be summarized by number and percentage of study participants meeting the definition of ORR along with the corresponding exact 95% CIs. DoR, defined as the duration (days) from initial response to disease relapse, progression, or death will be descriptively analyzed using Kaplan-Meier methods. The number of study participants achieving DoR at 3, 6, 9, and 12 months will also be calculated. Exploratory efficacy analyses include changes from Baseline in CBC counts, CAR T cells, cytokines, and CRP levels.

    Time frame: 1 year

07

Study locations

5 sites
  • City of Hope
    Duarte, California 91010, United States
  • University of California San Francisco
    San Francisco, California 94115, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • MD Anderson
    Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2020 to primary completion in Oct 2022, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2019
First posted
Nov 21, 2019
StartActual
Apr 30, 2020
Primary completionActual
Oct 19, 2022
CompletionActual
Oct 19, 2022
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04171843
Lead sponsor
Precision BioSciences, Inc.
Responsible party
Sponsor
First posted
Nov 21, 2019
Start date
Apr 30, 2020
Primary completion
Oct 19, 2022
Completion
Oct 19, 2022
Last update
Sep 21, 2023

Study contacts

Monika Vainorius, MD
study chair · Precision BioSciences, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nirogacestat

Start the discussion